Given these limitations, a randomized phase III trial in melanoma showed that combined inhibition of PD-1 and LAG-3 resulted in improved clinical outcomes (78), suggesting that targeting PD-1 and LAG-3, rather than PD-1 and CTLA-4, could be a safer and potentially more effective strategy in OCCC. The gene discussed is LAG3; the disease is melanoma.